BACKGROUND: The outcome of children with refractory/relapsed malignancies remains poor and novel therapies are urgently required. One of the promising approaches is metronomic chemotherapy. We present the clinical results of 74 children with advanced solid tumors treated according to treatment recommendation with data registry in three European pediatric centers. METHODS: COMBAT (Combined Oral Metronomic Biodifferentiating Antiangiogenic Treatment) included low-dose daily temozolomide, etoposide, celecoxib, vitamin D, fenofibrate and retinoic acid. From 2004 to 2010, 74 children were enrolled. RESULTS: The 2-year overall survival (OS) was 43.1% (median 15.4, range 1.3-69.9 months). Of the 74 patients, 50 patients (68%) died and 24 are alive: 6 (8%) with progressive disease, 7 (9%) with stable disease/partial response and 11 (15%) in complete response. Median time to response was 6 months. Of 62 patients with initially measurable disease, 25 (40%) had radiological response or stable disease. Fourteen of 25 showing clinical benefit responded within the first 6 months. The treatment was well tolerated on an outpatient basis. Regarding non-hematological toxicity of grade ≥2, hepatotoxicity of grade 3 occurred in 8 children and grade 3 cheilitis in 16 children. CONCLUSION: COMBAT is a feasible and effective treatment option for patients with relapsing/refractory malignancies. The treatment is well tolerated with a low acute toxicity profile.
BACKGROUND: The outcome of children with refractory/relapsed malignancies remains poor and novel therapies are urgently required. One of the promising approaches is metronomic chemotherapy. We present the clinical results of 74 children with advanced solid tumors treated according to treatment recommendation with data registry in three European pediatric centers. METHODS: COMBAT (Combined Oral Metronomic Biodifferentiating Antiangiogenic Treatment) included low-dose daily temozolomide, etoposide, celecoxib, vitamin D, fenofibrate and retinoic acid. From 2004 to 2010, 74 children were enrolled. RESULTS: The 2-year overall survival (OS) was 43.1% (median 15.4, range 1.3-69.9 months). Of the 74 patients, 50 patients (68%) died and 24 are alive: 6 (8%) with progressive disease, 7 (9%) with stable disease/partial response and 11 (15%) in complete response. Median time to response was 6 months. Of 62 patients with initially measurable disease, 25 (40%) had radiological response or stable disease. Fourteen of 25 showing clinical benefit responded within the first 6 months. The treatment was well tolerated on an outpatient basis. Regarding non-hematological toxicity of grade ≥2, hepatotoxicity of grade 3 occurred in 8 children and grade 3 cheilitis in 16 children. CONCLUSION: COMBAT is a feasible and effective treatment option for patients with relapsing/refractory malignancies. The treatment is well tolerated with a low acute toxicity profile.
Authors: M Grabacka; P Waligorski; A Zapata; D A Blake; D Wyczechowska; A Wilk; M Rutkowska; H Vashistha; R Ayyala; T Ponnusamy; V T John; F Culicchia; A Wisniewska-Becker; K Reiss Journal: J Physiol Pharmacol Date: 2015-04 Impact factor: 3.011
Authors: Nathan J Robison; Kee Kiat Yeo; Adrian P Berliner; Jemily Malvar; Michael A Sheard; Ashley S Margol; Robert C Seeger; Teresa Rushing; Jonathan L Finlay; Richard Sposto; Girish Dhall Journal: J Neurooncol Date: 2018-02-09 Impact factor: 4.130
Authors: Anna Wilk; Dorota Wyczechowska; Adriana Zapata; Matthew Dean; Jennifer Mullinax; Luis Marrero; Christopher Parsons; Francesca Peruzzi; Frank Culicchia; Augusto Ochoa; Maja Grabacka; Krzysztof Reiss Journal: Mol Cell Biol Date: 2014-10-20 Impact factor: 4.272
Authors: Miroslava Krzyzankova; Silvia Chovanova; Petr Chlapek; Matej Radsetoulal; Jakub Neradil; Karel Zitterbart; Jaroslav Sterba; Renata Veselska Journal: Tumour Biol Date: 2014-05-06
Authors: Petr Chlapek; Jakub Neradil; Martina Redova; Karel Zitterbart; Jaroslav Sterba; Renata Veselska Journal: Cancer Cell Int Date: 2014-06-13 Impact factor: 5.722
Authors: Karen D Wright; Xiaopan Yao; Wendy B London; Pei-Chi Kao; Lia Gore; Stephen Hunger; Russ Geyer; Kenneth J Cohen; Jeffrey C Allen; Howard M Katzenstein; Amy Smith; Jessica Boklan; Kellie Nazemi; Tanya Trippett; Matthias Karajannis; Cynthia Herzog; Joseph Destefano; Jennifer Direnzo; Jay Pietrantonio; Lianne Greenspan; Danielle Cassidy; Debra Schissel; John Perentesis; Mitali Basu; Tomoyuki Mizuno; Alexander A Vinks; Sanjay P Prabhu; Susan N Chi; Mark W Kieran Journal: Pediatr Blood Cancer Date: 2020-11-02 Impact factor: 3.838